Covaxin phase 2 trials show vaccine safe, induces immune response
The Hindu
India's first indigenous vaccine against COVID-19, Covaxin, is safe and generates immune response without any serious side effects, according to the interim results of the phase 2 trials published in The Lancet Infectious Diseases journal.
The authors of the study noted that the phase 2 results did not asses the efficacy of the vaccine codenamed BBV152.
More Related News

Climate scientists and advocates long held an optimistic belief that once impacts became undeniable, people and governments would act. This overestimated our collective response capacity while underestimating our psychological tendency to normalise, says Rachit Dubey, assistant professor at the department of communication, University of California.







